title: Loss of bone mineral density and secondary hyperparathyroidism are complications of autologous stem cell transplantation.
abstract: Patients who underwent autologous stem cell transplantation (ASCT) are prone to decreased bone mineral density (BMD). We measured BMD in 180 patients who underwent ASCT for hematologic malignancies. Patients were evaluated with a median of 6.2 years after ASCT. Twenty patients who received only chemotherapy were evaluated as controls. The loss of bone mass was greater during the first year after ASCT, since majority of patients recover BMD and normalize bone turnover markers during the following years. After ASCT, over half of the patients show osteopenia or osteoporosis independent of the sex. According to the results of other groups, our results emphasize the potential usefulness of antiresorptive agents to prevent or treat post-ASCT osteopenia or osteoporosis, and the importance of the measurement of BMD as an integral component to the follow-up of ASCT.
authors.affiliation: Department of Biomedical Sciences and Human Oncology, Section of Internal Medicine and Clinical Oncology, University of Bari, Bari, Italy. ria@dimo.uniba.it
authors.forename: Roberto
authors.initials: R
authors.lastname: Ria
authors.forename: Anna Maria
authors.initials: AM
authors.lastname: Scarponi
authors.forename: Franca
authors.initials: F
authors.lastname: Falzetti
authors.forename: Stelvio
authors.initials: S
authors.lastname: Ballanti
authors.forename: Mauro
authors.initials: M
authors.lastname: Di Ianni
authors.forename: Paolo
authors.initials: P
authors.lastname: Sportoletti
authors.forename: Michele
authors.initials: M
authors.lastname: Cimminiello
authors.forename: Cristiana
authors.initials: C
authors.lastname: Gasbarrino
authors.forename: Benedetta
authors.initials: B
authors.lastname: Pallone
authors.forename: Angelo
authors.initials: A
authors.lastname: Vacca
authors.forename: Franco
authors.initials: F
authors.lastname: Dammacco
authors.forename: Elmo
authors.initials: E
authors.lastname: Mannarino
authors.forename: Antonio
authors.initials: A
authors.lastname: Tabilio
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D015519:Bone Density; D001851:Bone Diseases, Metabolic / Q000209:etiology; D001842:Bone and Bones / Q000473:pathology; D005260:Female; D019337:Hematologic Neoplasms / Q000628:therapy*; D006801:Humans; D006961:Hyperparathyroidism / Q000175:diagnosis* / Q000209:etiology*; D008297:Male; D008875:Middle Aged; D010024:Osteoporosis / Q000209:etiology; D033581:Stem Cell Transplantation / Q000009:adverse effects*; D014182:Transplantation, Autologous / Q000009:adverse effects*
chemical_list: D000970:Antineoplastic Agents